

April 25, 2016

Interprotein Corporation
A.I. Squared, Inc.

Interprotein Corporation and A.I. Squared, Inc. Sign a Joint Research and Development AI Drug Discovery Agreement

Interprotein Corporation (President: Masato Hosoda, Headquarters: Kita-ku, Osaka) and A.I. Squared, Inc. (CEO: Masaki Ishida, Headquarters: Minato-ku, Tokyo) announced today that the two companies have signed a joint research and development agreement for analysis of protein-protein interaction along of drug discovery.

Both companies will collaborate to develop unique novel pharmaceutical utilizing the expertise of Interprotein Corporation in molecular designing technologies and excellent artificial intelligence technology including deep learning know-how of A.I. Squared, Inc. together for paradigm creation of new drug discovery.

About Interprotein Corporation

Interprotein Corporation is focusing on PPIs as drug targets with great potential and conducting drug discovery research of PPI antagonists and agonists using two technology platforms, i.e. helix-loop-helix peptides (HLHP) and INTERprotein's Engine for New Drug Design (INTENDD®). HLHP is a conformationally -constrained peptide with two helices linked on both sides, and INTENDD® is a strategic approach for structure-based drug discovery (SBDD) of small molecules and can efficiently identify new drug-like scaffolds by Structure-Based Scaffold Generation (SBSG®) method.

About A.I. Squared, Inc.

A.I. Squared, Inc. is an artificial intelligence based solution provider focusing on business process improvement utilizing recognition technologies for voice, text, and image. Established since December 2015, as a subsidiary of BroadBand Tower, Inc. (JASDAQ 3776). Located in Tokyo.

Interprotein



Contact	
Interprotein Corporation Komatsu, Director for BD Dept. TEL/FAX: +81-42-770-9477 E-mail: info@interprotein.com http://www.interprotein.com	A.I. Squared, Inc. Ogino, Director TEL: +81-3-5510-2020 E-mail: info@ai2-jp.com http://www.ai2-jp.com